Physician profile
Hima B Ravi
NPI 1326147158
$2,746.68
in general payments reported to CMS, 2019-2025
36 companies · $954 in 2025
The $954 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2020: $233 · 2021: $370 · 2022: $247 · 2023: $301 · 2024: $516 · 2025: $954.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,771.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,770.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $386.22 | 2021-2025 | |
| Amgen INC. | $304.86 | 2019-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $241.22 | 2019-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $183.23 | 2019-2025 | |
| Glaxosmithkline, LLC. | $168.51 | 2022-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Novo Nordisk INC | $149.28 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $131.65 | 2021-2025 | |
| Eisai INC. | $118.88 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $97.22 | 2019-2024 | |
| Radius Health, INC. | $89.88 | 2023-2025 | Tymlos |
| Allergan, INC. | $88.99 | 2019-2020 | |
| Lundbeck LLC | $71.44 | 2024 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $64.69 | 2020-2025 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.36 | 2020-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $50.09 | 2020-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $49.90 | 2024-2025 | Gemtesa |
| Mylan Specialty L.P. | $48.00 | 2023 | Yupelri |
| Corcept Therapeutics | $46.05 | 2025 | Korlym |
| Inspire Medical Systems, INC. | $37.62 | 2024 | Inspire |
| Abbott Laboratories | $35.88 | 2022-2025 | Freestyle Libre 3 |
| Globus Medical, INC. | $32.61 | 2025 | Senza |
| Nestle Healthcare Nutrition INC. | $29.75 | 2023 | |
| Biogen, INC. | $29.15 | 2021 | |
| Sanofi-Aventis U.S. LLC | $28.87 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.38 | 2025 | Gattex |
| Viatris Specialty LLC | $22.84 | 2025 | Yupelri |
| Astellas Pharma US INC | $22.35 | 2020 | |
| Verona Pharma, INC. | $20.56 | 2025 | Ohtuvayre |
| Axsome Therapeutics, INC. | $19.66 | 2023 | Sunosi |
| Phathom Pharmaceuticals, INC. | $17.74 | 2024 | Voquezna |
| Amarin Pharma, INC. | $15.40 | 2020 | |
| Paratek Pharmaceuticals, INC. | $14.78 | 2025 | Nuzyra |
| Merck Sharp & Dohme LLC | $14.40 | 2024 | Capvaxive |
| Esperion Therapeutics, INC. | $14.07 | 2025 | Nexletol |
| Exact Sciences Corporation | $13.51 | 2025 | The Cologuard Plus Collection Kit |
| Dexcom, INC. | $11.64 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hima Ravi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.